<table className="table">
  <caption>
    <p>
      Characteristics of Drug-Induced Parenchymal Lung Diseases
    </p>
  </caption>
  <thead>
    <tr>
      <th rowSpan="1" colSpan="1">
        <p>
          Drug
        </p>
      </th>
      <th rowSpan="1" colSpan="1">
        <p>
          Clinical Points
        </p>
      </th>
      <th rowSpan="1" colSpan="1">
        <p>
          Radiographic Findings and Treatment
        </p>
      </th>
    </tr>
  </thead>
  <tbody>
    <tr className="group_1-1 row-odd">
      <td rowSpan="1" colSpan="1">
        <p>
          Amiodarone
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          More common in:
        </p>
        <p>
          Older patients
        </p>
        <p>
          Patients taking increased dosage and a higher cumulative dose
        </p>
        <p>
          First year of therapy (but drug-induced DPLD can occur later)
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Multiple radiographic presentations, including ground-glass opacities, subpleural nodules, and reticular abnormalities
        </p>
        <p>
          Very long half-life prolongs clearance from the pulmonary parenchyma
        </p>
        <p>
          Rare improvement with discontinuation of the drug alone; glucocorticoids often necessary
        </p>
        <p>
          High risk for recurrence with tapering of glucocorticoids
        </p>
      </td>
    </tr>
    <tr className="group_1-2 row-even">
      <td rowSpan="1" colSpan="1">
        <p>
          Methotrexate
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Occurs in &lt;5% of treated patients
        </p>
        <p>
          Unpredictable time to presentation
        </p>
        <p>
          No clear correlation between dose and disease severity
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Diffuse reticular and ground-glass attenuation
        </p>
        <p>
          General improvement after stopping medication
        </p>
        <p>
          Glucocorticoids often given; duration based on response
        </p>
      </td>
    </tr>
    <tr className="group_1-3 row-odd">
      <td rowSpan="1" colSpan="1">
        <p>
          Nitrofurantoin
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Acute (more common):
        </p>
        <p>
          Fevers, chills, cough, shortness of breath, chest pain; rash in 10% to 20% of patients
        </p>
        <p>
          Peripheral eosinophilia common
        </p>
        <p>
          Chronic:
        </p>
        <p>
          Distinct from the acute form
        </p>
        <p>
          Onset months to years after prolonged exposure
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Acute: Faint bilateral septal lines in the lower lobes; moderate pleural effusions possible; often resolves with discontinuation but will recur with repeat exposure
        </p>
        <p>
          Chronic: Reticular opacities with subpleural lines and thickened peri-bronchovascular areas; possible benefit of glucocorticoids from anecdotal reports
        </p>
      </td>
    </tr>
    <tr className="group_1-4 row-even">
      <td rowSpan="1" colSpan="1">
        <p>
          Epidermal growth factor receptor-targeted agents and ICIs
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Nonspecific presentation: dyspnea, dry cough, fever, deterioration of pre-existing respiratory symptoms; can mimic infections or progression of background malignancy
        </p>
        <p>
          Preexisting lung disease, as well as previous or concurrent radiation therapy, may increase risk of ICI-induced lung disease
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Multiple patterns, including interstitial lung disease, organizing pneumonia, ground-glass opacities, pneumonitis, pleural effusion, sarcoid-like reaction, acute respiratory distress syndrome
        </p>
        <p>
          Withhold offending agent; glucocorticoids for disease progression or severe disease at presentation
        </p>
      </td>
    </tr>
    <tr className="group_1-5 row-odd">
      <td rowSpan="1" colSpan="1">
        <p>
          Busulfan
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Occurs in &lt;8% of treated patients
        </p>
        <p>
          Used as a preparative regimen for hematopoietic stem cell transplantation; often combined with other agents associated with pulmonary toxicity
        </p>
        <p>
          Occurrence of injury typically 30 d to 1 y after exposure
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Multiple patterns, including ground-glass opacities, reticulation, bibasilar septal lines, asymmetric peripheral and peribronchial consolidation, centrilobular nodules, and dependent consolidation
        </p>
        <p>
          Optimal treatment unknown and is often supportive; glucocorticoids used for more progressive disease
        </p>
      </td>
    </tr>
    <tr className="group_1-6 row-even">
      <td rowSpan="1" colSpan="1">
        <p>
          Bleomycin
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Increased risk for toxicity with cumulative dose, older age, kidney disease, concomitant chemotherapy or irradiation
        </p>
        <p>
          Typically subacute presentation 1 to 6 mo after exposure; may show hypersensitivity pneumonitis, diffuse alveolar damage, or usual interstitial pneumonia pathologically but with more rapid clinical onset and progressive course
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Imaging patterns suggest multiple possible pathologic findings:
        </p>
        <p>
          Consolidation with ground glass (diffuse alveolar damage)
        </p>
        <p>
          Septal line thickening, traction bronchiectasis, and honeycomb change (end-stage fibrosis)
        </p>
        <p>
          Patchy ground glass with subpleural consolidation or peribronchial consolidation (organizing pneumonia)
        </p>
        <p>
          Diffuse ground glass with centrilobular micronodules (hypersensitivity pneumonitis)
        </p>
        <p>
          Glucocorticoids used for more severe disease; potential disease recurrence with tapering of steroids
        </p>
      </td>
    </tr>
  </tbody>
</table>
